KR20090040025A - Novel lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use thereof - Google Patents
Novel lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use thereof Download PDFInfo
- Publication number
- KR20090040025A KR20090040025A KR1020070105583A KR20070105583A KR20090040025A KR 20090040025 A KR20090040025 A KR 20090040025A KR 1020070105583 A KR1020070105583 A KR 1020070105583A KR 20070105583 A KR20070105583 A KR 20070105583A KR 20090040025 A KR20090040025 A KR 20090040025A
- Authority
- KR
- South Korea
- Prior art keywords
- dsr
- lactobacillus plantarum
- kimchi
- lactic acid
- lactobacillus
- Prior art date
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 26
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 25
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 25
- 235000021109 kimchi Nutrition 0.000 title abstract description 68
- 230000002401 inhibitory effect Effects 0.000 title abstract description 15
- 244000000010 microbial pathogen Species 0.000 title abstract description 3
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 43
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 241000607142 Salmonella Species 0.000 claims abstract description 21
- 239000002253 acid Substances 0.000 claims abstract description 18
- 230000003115 biocidal effect Effects 0.000 claims abstract description 18
- 239000011780 sodium chloride Substances 0.000 claims abstract description 16
- 241000588724 Escherichia coli Species 0.000 claims abstract description 15
- 241000186779 Listeria monocytogenes Species 0.000 claims abstract description 14
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 12
- 241000607447 Yersinia enterocolitica Species 0.000 claims abstract description 10
- 229940098232 yersinia enterocolitica Drugs 0.000 claims abstract description 10
- 241001138501 Salmonella enterica Species 0.000 claims abstract description 8
- 208000015181 infectious disease Diseases 0.000 claims abstract description 4
- 241000186660 Lactobacillus Species 0.000 claims description 64
- 229940039696 lactobacillus Drugs 0.000 claims description 60
- 239000007858 starting material Substances 0.000 claims description 27
- 241000193755 Bacillus cereus Species 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 230000000845 anti-microbial effect Effects 0.000 claims description 11
- 235000021107 fermented food Nutrition 0.000 claims description 11
- 239000006041 probiotic Substances 0.000 claims description 10
- 235000018291 probiotics Nutrition 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000000529 probiotic effect Effects 0.000 claims description 9
- 235000013373 food additive Nutrition 0.000 claims description 8
- 239000002778 food additive Substances 0.000 claims description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 2
- 210000000941 bile Anatomy 0.000 abstract description 15
- 240000001817 Cereus hexagonus Species 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 230000015784 hyperosmotic salinity response Effects 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 162
- 241000894006 Bacteria Species 0.000 description 90
- 239000004310 lactic acid Substances 0.000 description 81
- 235000014655 lactic acid Nutrition 0.000 description 81
- 239000002609 medium Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 12
- 229920001817 Agar Polymers 0.000 description 11
- 239000008272 agar Substances 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000001888 Peptone Substances 0.000 description 8
- 108010080698 Peptones Proteins 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 229940041514 candida albicans extract Drugs 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 235000019319 peptone Nutrition 0.000 description 8
- 239000012138 yeast extract Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 240000007124 Brassica oleracea Species 0.000 description 6
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 6
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 6
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 241000220259 Raphanus Species 0.000 description 5
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 5
- 235000015278 beef Nutrition 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- -1 sketol Chemical compound 0.000 description 4
- 240000002234 Allium sativum Species 0.000 description 3
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 3
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 3
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 3
- 206010008631 Cholera Diseases 0.000 description 3
- 241000192001 Pediococcus Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 239000001177 diphosphate Substances 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000004611 garlic Nutrition 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 229940050410 gluconate Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940099596 manganese sulfate Drugs 0.000 description 3
- 239000011702 manganese sulphate Substances 0.000 description 3
- 235000007079 manganese sulphate Nutrition 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000006916 nutrient agar Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004460 silage Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 2
- 240000006108 Allium ampeloprasum Species 0.000 description 2
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000001728 capsicum frutescens Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 235000021574 pickled cabbage Nutrition 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000206594 Carnobacterium Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QMYDHJSXOZCPFF-YMRLNLKISA-N OC[C@@H](O)[C@H](O)[C@@H](O)C=O.C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O.C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O QMYDHJSXOZCPFF-YMRLNLKISA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
- 235000005733 Raphanus sativus var niger Nutrition 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241000202221 Weissella Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930195726 aldehydo-L-xylose Natural products 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 병원성 세균의 생육을 억제하는 유산균 및 이의 용도에 관한 것으로서, 보다 상세하게는 병원성 세균의 생육을 저해하고 내산성, 내염성, 내답즙성 및 항생제 내성이 우수한 락토바실러스 플란타륨 DSR 330 및 이의 용도에 관한 것이다.The present invention relates to lactic acid bacteria and their use to inhibit the growth of pathogenic bacteria, and more particularly, Lactobacillus plantarium DSR 330 and its use, which inhibit the growth of pathogenic bacteria and are excellent in acid resistance, flame resistance, juice resistance and antibiotic resistance. It is about.
인돌, 스케톨, 페놀, 아민 및 암모니아 등의 유해물질은 생산하지 않으면서 인간에게 유익한 젖산을 생산하는 유산균은 동물의 장내에서 가장 많은 밀도로 존재하며, 특히 소화흡수가 일어나는 소장에서 우점균으로 자리 잡고 있다(Barnes, F. M. et.al., Amer . J. Clin . Nutr ., 33, 2426-2433, 1980; Salanitro, J. P. et.al., Appl . Environ . Microbiol ., 33, 79-84, 1977).Lactobacillus, which produces lactic acid that is beneficial to humans without producing harmful substances such as indole, sketol, phenol, amine, and ammonia, is present at the highest density in the intestines of animals, especially as the dominant bacteria in the small intestine where digestive absorption occurs. holding (Barnes, FM et.al., Amer J. Clin Nutr, 33, 2426-2433, 1980;...... Salanitro, JP et.al., Appl Environ Microbiol, 33, 79-84, 1977 ).
상기 유산균에는 대표적으로 카르노박테리움속(Carnobacterium), 엔테로코커스속(Enterococcus), 락토바실러스속(Lactobacillus), 락토코커스속(Lactococcus), 류코노스톡속(Leuconostoc), 페디오코커스속(Pediococcus), 스트렙토코커스 속(Streptococcus), 테트라제노코커스속(Tetragenococcus), 바고코커스속(Vagococcus) 바이쎌라속(Weissella) 및 비피더스속(Bifidobacterium) 균주 등이 포함된다(Stiles, M. E. et.al., Int. J. Food Microbiol., 36, 1-29, 1997). 특히 락토바실러스속 균주는 안전성이 우수하여 여러 연구에 사용되고 있으며 정상적으로 사람을 포함한 동물의 장관에 일정한 균총을 생성하고 면역증진작용, 유해독소의 중화 및 합성차단, 영양분의 소화흡수의 증대 그리고 여러 유익한 생리활성을 나타내는 것으로 이미 잘 알려져 있어 사람은 물론 동물에게도 많이 투여되고 있다.The lactic acid bacteria are typically Carnobacterium, Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, Pediococcus, Pediococcus, Streptococcus, Teteragenococcus, Bagococcus Weissella and Bifidobacterium strains, and the like (Stiles, ME et.al., Int. J.). Food Microbiol. , 36, 1-29, 1997). In particular, the Lactobacillus strain is used in various studies because of its excellent safety, and normally produces a certain flora in the intestinal tract of animals including humans, enhances immune function, neutralizes and synthesizes harmful toxins, increases digestive absorption of nutrients, and various beneficial physiology. It is already well known to show activity, and has been administered to humans as well as animals.
한편 병원성 세균에는 대표적으로 식중독을 일으키는 살모넬라 속균(Salmonella spp.), 스타필로코코스 에우리우스(Staphylococcus aureus), 장독성 대장균(enterotoxigenic E. coli), 바실러스 세레우스(B.cereus), 여시니아 엔테로콜리티카(Yersinia enterocolitica) 및 리스테리아 모노사이토게네스(Listeria monocytogenes)가 있으며 특히 스타필로코코스 에우리우스(Staphylococcus aureus)는 식중독뿐만 아니라 피부의 화농·중이염·방광염 등 화농성 질환을 유발하는 세균으로 널리 알려져 있다.Pathogenic bacteria include Salmonella spp., Staphylococcus aureus, Entero-otoxigenic E. coli, B. cereus, and Y. cynobacteria. There are Yersinia enterocolitica and Listeria monocytogenes. In particular, Staphylococcus aureus is widely known as a bacterium that causes not only food poisoning but also purulent diseases such as purulent, otitis media and cystitis of the skin.
상기 병원성 세균에 의한 감염증을 예방 또는 치료하기 위해 지금까지는 주로 합성 또는 천연 항생제를 사용하였다. 그러나 합성 항생제의 사용은 내성 및 잔류 등의 문제로 사용량에 대한 규제가 엄격한데다 장내 유익한 균총 또한 파괴하기 때문에 정상 균총에 의한 병원성 세균 감염에 대한 예방 효과를 잃게 한다. 또한 천연 항생제로 알칼로이드(alkaloid), 후라보노이드(flavonoid), 피토알렉 신(Phytoalexin), 항균 펩타이드, 유기산 및 지방산이 알려져 있지만 대부분은 색취, 안정성 저하, 좁은 항균 스펙트럼 및 제형상의 문제점으로 인하여 상용화되지 못하고 있는 실정이다.Until now, mainly synthetic or natural antibiotics have been used to prevent or treat infection caused by the pathogenic bacteria. However, the use of synthetic antibiotics has severe restrictions on usage due to problems such as resistance and retention, and also destroys the beneficial flora in the intestine, thus losing the protection against pathogenic bacterial infections caused by normal flora. Alkaloids, flavonoids, phytoalexin, antimicrobial peptides, organic acids and fatty acids are known as natural antibiotics, but most of them are not commercialized due to coloration, poor stability, narrow antimicrobial spectrum and formulation problems. There is a situation.
이러한 문제점으로 인하여 상기 병원성 세균에 대한 천연 항균제로 유산균이 크게 각광받을 수 있으나 실질적인 항균효과를 나타내기 위해서는 다음과 같은 특징들이 요구되는데, 구체적으로 섭취 후 장내의 소화기관들에서 분비되는 여러 물질들을 견뎌낼 수 있는 내산성 및 내담즙성 등을 나타내어 장내 생존력이 우수해야 하며, 낮은 pH, 영양소 소비, 전위차 감소, 과산화수소 생산 및 항균물질 생산(예, 박테리오신) 등에 의한 병원성 세균 억제능이 우수해야 한다. 특히, 유산균을 이용한 항균제는 병원성 세균들의 생육을 저해함과 동시에 여러 가지 문제를 나타내는 항생제 사용량을 낮추며, 인체에 안전하기 때문에 식품 제조 과정에서 유용하게 사용될 수 있다.Due to this problem, lactic acid bacteria can be greatly spotlighted as a natural antimicrobial agent against the pathogenic bacteria, but the following characteristics are required to exhibit a practical antimicrobial effect, and specifically, to endure various substances secreted from the intestinal digestive organs after ingestion. It should be excellent in intestinal viability by showing acid resistance and bile resistance, and should be excellent in inhibiting pathogenic bacteria due to low pH, nutrient consumption, reduction of potential difference, hydrogen peroxide production and antimicrobial production (eg bacteriocin). In particular, the antimicrobial agent using lactic acid bacteria, while inhibiting the growth of pathogenic bacteria and at the same time lower the amount of antibiotics showing a variety of problems, and can be useful in the food manufacturing process because it is safe for the human body.
따라서 상기 병원성 세균에 대한 항균효과가 있으며 내산성, 내염성, 내담즙성 및 항생제 내성이 우수한 새로운 천연 항균제인 유산균의 개발이 절실히 요구되고 있다.Therefore, there is an urgent need for the development of lactic acid bacteria, a new natural antibacterial agent that has an antimicrobial effect against the pathogenic bacteria and is excellent in acid resistance, flame resistance, bile resistance and antibiotic resistance.
한편, 김치는 우리나라 전통 고유의 발효식품으로서 한국인의 장 건강에 기여하는 대표적인 유산균 공급원이다. 최근 들어 김치는 배추와 무 등 김치 재료와 김치발효에 참여하는 여러 유산균의 기능이 복합적으로 나타나 항 돌연변이와 항암 효과 등 여러 유용한 기능들을 보유하고 있다는 것이 알려지면서 1990년대 이후 본격적으로 상품화되어 국내 수요량과 수출량이 꾸준히 증가하고 있는 추세이다. 이 러한 김치의 맛을 내기 위한 발효에 관여하는 미생물로는 락토바실러스 플랜타룸(L.plantarum), 락토바실러스 브레비스(L. brevis), 락토코커스(Lactococcus), 류코노스톡(Leuconostoc), 스트렙토코커스(Streptococcus), 페디오코커스(Pediococcus) 등이 있으며 발효단계에 따라 전체 균총을 형성하는 균의 종류와 구성비율이 변하게 된다.Kimchi, on the other hand, is Korea's traditional fermented food, a representative source of lactic acid bacteria that contributes to Korean intestinal health. Recently, kimchi is known to possess various useful functions such as kimchi ingredients such as Chinese cabbage and radish and various lactic acid bacteria that participate in kimchi fermentation, and has various useful functions such as anti-mutation and anticancer effects. Exports are steadily increasing. Microorganisms involved in the fermentation to taste the kimchi include L. plantarum, L. brevis, Lactococcus, Leuconostoc, Streptococcus Streptococcus) and Pediococcus, etc., and the type and composition ratio of the bacteria forming the total flora vary depending on the fermentation stage.
따라서 최근에는 김치에서 유래되는 유산균을 분리한 후, 김치제조시 스타터(starter)로 첨가함으로써 김치의 맛과 발효를 조절하려는 연구들이 많이 진행되고 있는데, 대한민국 등록특허 제1989-4894호에 차아염소산나트륨과 루코노스톡 메센테로이드 균주를 첨가하여 산패가 억제되고 보존성이 연장된 김치를 제조하는 방법이 개시된 바 있고, 대한민국 등록특허 제0181009호에 루코노스톡 파라메센테로이드와 루코노스톡 메센테로이드 균주를 혼합 첨가함으로써 맛이 좋을 뿐만 아니라 락토바실러스 속 균주의 생육을 억제하여 산패가 지연되도록 한 김치의 제조방법이 개시된 바 있다. 그러나 상기 종래기술의 루코노스톡 메센테로이드는 내산성이 약하기 때문에 김치의 발효가 점차 진행되면서 균주의 수가 감소되어 김치의 신선한 맛을 지속적으로 유지시킬 수 없다는 문제점이 있다. 따라서 김치의 품질을 향상시키고 건강을 위한 기능성을 부가할 수 있는 새로운 유산균 스타터에 대한 개발이 절실히 요구되는 실정이다.Therefore, in recent years, many studies have been conducted to control the taste and fermentation of kimchi by separating the lactic acid bacteria derived from kimchi and adding it as a starter during the production of kimchi. A method for producing kimchi with suppressed rancidity and extended shelf life has been disclosed by the addition of a luconosstock mesentoid strain and a mixture of ruconosstock paramesenteroid and luconosstock mesentoid strain in Korean Patent No. 0181009. It has been disclosed a method of producing kimchi that not only tastes good by addition but also inhibits the growth of Lactobacillus strains to delay rancidity. However, since the conventional rukonostock mecetheroidoid has weak acid resistance, the number of strains decreases as the fermentation of kimchi gradually progresses, and thus there is a problem that the fresh taste of kimchi cannot be maintained continuously. Therefore, the development of a new lactic acid bacteria starter that can improve the quality of kimchi and add functionality for health is urgently required.
이에 본 발명자들은 병원성 세균의 생육을 억제할 수 있는 신규한 유산균을 한국인의 대표적인 발효식품인 김치에서 찾고자 연구를 거듭하던 중, 병원성 세균을 억제하고 내산성, 내염성, 내담즙성 및 항생제 내성이 우수한 신규 김치 유산균 을 분리 및 동정함으로써 본 발명을 완성하였다.Therefore, the inventors of the present invention have been trying to find a novel lactic acid bacteria that can inhibit the growth of pathogenic bacteria in kimchi, a representative fermented food of Korean, while suppressing pathogenic bacteria and excellent in acid resistance, flame resistance, bile resistance and antibiotic resistance. The present invention was completed by separating and identifying kimchi lactic acid bacteria.
따라서 본 발명의 목적은 병원성 세균의 생육을 억제하고 내산성, 내염성, 내담즙성 및 항생제 내성이 우수한 락토바실러스 플란타륨 DSR 330 및 이의 용도를 제공하는 것이다.It is therefore an object of the present invention to provide Lactobacillus plantarium DSR 330 and its use which inhibit the growth of pathogenic bacteria and which are excellent in acid resistance, flame resistance, bile resistance and antibiotic resistance.
상기와 같은 목적을 달성하기 위하여, 본 발명은 병원성 세균의 생육을 억제하고 항생제 내성이 우수하며 pH 2.5 ~ 5에서 내산성, NaCl 2 ~ 15 %에서 내염성 및 옥스갈(oxgall) 0.3 ~ 3 %에서 내담즙성을 갖는 락토바실러스 플란타륨을 제공한다.In order to achieve the above object, the present invention suppresses the growth of pathogenic bacteria, excellent antibiotic resistance, acid resistance at pH 2.5-5, flame resistance at NaCl 2-15% and oxgall at 0.3-3% It provides Lactobacillus plantarium having biliary properties.
본 발명의 다른 목적을 달성하기 위하여 본 발명은 상기 락토바실러스 플란타륨 또는 이의 배양물을 함유하는 정장용, 생균제, 사료용, 항균용, 식품첨가용 및 약학적 조성물을 제공한다.In order to achieve another object of the present invention, the present invention provides a formal, probiotic, feed, antibacterial, food additives and pharmaceutical compositions containing the Lactobacillus plantarium or its culture.
또한, 본 발명의 다른 목적을 달성하기 위하여 본 발명은 상기 락토바실러스 플란타륨 또는 이의 배양물을 함유하는 발효식품을 제공한다.In addition, the present invention provides a fermented food containing the Lactobacillus plantarium or a culture thereof to achieve another object of the present invention.
또한, 본 발명은 상기 락토바실러스 플란타륨 또는 이의 배양물을 스타터로 이용하여 발효식품을 제조하는 방법을 제공한다.The present invention also provides a method for producing a fermented food using the Lactobacillus plantarium or its culture as a starter.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 락토바실러스 플란타륨은 병원성 세균의 생육을 억제하고 내산성, 내염성, 내담즙성 및 항생제 내성을 가지는 특징이 있다. 특히, 김치에서 분리한 본 발명의 락토바실러스 플란타륨 DSR 330은 병원성 세균인 스타필로코코스 에우리우스(Staphylococcus aureus), 대장균(E.coli), 바실러스 세레우스(B.cereus), 살모넬라 타이피뮤림(Salmonella typimurium), 살모넬라 콜레라수이스(Salmonella choleraesuis), 여시니아 엔테로콜리티카(Yersinia enterocolitica) 및 리스테리아 모노사이토게네스(Listeria monocytogenes)로 이루어진 군에서 선택된 하나 이상의 균의 생육을 억제하는 활성이 있으며, pH 2.5 ~ 5에서 내산성, NaCl 2 ~ 15 %에서 내염성 및 옥스갈(oxgall) 0.3 ~ 3 % 내담즙성을 가지는 특징이 있다(실시예 1-2 내지 1-7 참조).Lactobacillus plantarium of the present invention is characterized by inhibiting the growth of pathogenic bacteria and having acid resistance, flame resistance, bile resistance and antibiotic resistance. In particular, the Lactobacillus plantarium DSR 330 of the present invention isolated from kimchi is a pathogenic bacterium Staphylococcus aureus, E. coli, Bacillus cereus, Salmonella typhimurim (Salmonella typimurium), Salmonella choleraesuis, Yersinia enterocolitica and Listeria monocytogenes. It is characterized by having acid resistance at pH 2.5 to 5, salt resistance at
특히 본 발명의 락토바실러스 플란타륨은 pH 2.5에서 90 %이상 생존하여 강한 내산성을 가지고 NaCl 15 %에서 97 % 이상 생존하여 강한 내염성을 가지며 옥스갈(oxgall) 3 %에서 95 % 이상의 생존율을 보여 강한 내담즙성을 가진다. In particular, the Lactobacillus plantarium of the present invention survives at least 90% at pH 2.5, has strong acid resistance, survives at least 97% at 15% NaCl, has strong flame resistance, and has a survival rate of at least 95% at 3% of oxgall. Has bile resistance
본 발명의 락토바실러스 플란타륨은 내산성, 내염성 및 내담즙성이 우수하기 때문에, 상기 균주를 경구 섭취하면 생체 내의 가혹한 환경, 즉 pH가 3 이하로 내려가는 산성 환경과 위장 및 소장에서 분비되는 소화효소 및 담즙산에 의해서도 생육이 우수해 장으로 도달할 수 있는 확률이 증가 될 수 있다. Since the Lactobacillus plantarium of the present invention is excellent in acid resistance, flame resistance, and bile resistance, oral ingestion of the strain is a digestive enzyme secreted from a harsh environment in vivo, that is, an acidic environment in which the pH is lowered to 3 or less, and the gastrointestinal and small intestine. And bile acids can also increase the probability of reaching the intestine is excellent growth.
또한 본 발명의 락토바실러스 플란타륨은 항생제 내성이 우수하기 때문에 항생제의 존재하에서도 생육이 가능해 생체 내에서 유익한 기능을 할 수 있다(실시예 1-6 참조).In addition, since the Lactobacillus plantarium of the present invention is excellent in antibiotic resistance, it is possible to grow even in the presence of antibiotics and thus have a beneficial function in vivo (see Example 1-6).
또한 본 발명의 락토바실러스 플란타륨은 항균력도 우수한 것으로 나타났다. 특히 본 발명의 유산균은 병원성 세균인 스타필로코코스 에우리우스(Staphylococcus aureus), 대장균(E.coli), 바실러스 세레우스(B.cereus), 살모넬라 타이피뮤림(Salmonella typimurium), 살모넬라 콜레라수이스(Salmonella choleraesuis), 여시니아 엔테로콜리티카(Yersinia enterocolitica) 및 리스테리아 모노사이토게네스(Listeria monocytogenes)로 이루어진 군에서 선택된 하나 이상의 균에 항균력이 있는 것으로 나타났다(실시예 1-7 참조).In addition, the Lactobacillus plantarium of the present invention was shown to have excellent antibacterial activity. In particular, the lactic acid bacteria of the present invention are pathogenic bacteria Staphylococcus aureus, Escherichia coli, E. coli, B. cereus, Salmonella typimurium, Salmonella cholera suis (Salmonella) choleraesuis), Yersinia enterocolitica and Listeria monocytogenes were found to have antimicrobial activity (see Example 1-7).
상기와 같은 병원성 세균의 생육을 억제하고 내산성, 내염성, 내담즙성 및 항생제 내성이 우수한 특징을 모두 가지고 있는 락토바실러스 플란타륨 균주는 본 발명에서 처음으로 제공되는 것이다.Lactobacillus plantarium strain that inhibits the growth of pathogenic bacteria as described above and has all of the characteristics of excellent resistance to acid, salt, bile and antibiotic resistance is provided for the first time in the present invention.
따라서 본 발명의 유산균은 인간 및 동물의 건강증진을 위한 용도, 즉 정장용, 생균제, 항균용, 사료용, 식품 첨가용 또는 약학적 조성물로 사용될 수 있다. 상기 조성물은 본 발명의 락토바실러스 플란타륨의 파쇄된 세포벽 분획, 생균, 사균, 건조균 또는 배양물을 유효성분으로 포함할 수 있으며, 부형제 또는 담체를 추가로 포함할 수 있다. 상기 배양물은 액체배지에서 배양한 배양액 자체, 상기 배양액을 여과 또는 원심분리하여 균주를 제거한 여액(원심분리한 상등액)등을 포함한다. 조성물 내 락토바실러스 플란타륨의 함량은 조성물의 용도 및 제형에 따라 달라질 수 있다. Therefore, the lactic acid bacteria of the present invention can be used for the purpose of improving the health of humans and animals, that is, for formal use, probiotics, antibacterial, feed, food additives or pharmaceutical compositions. The composition may include a crushed cell wall fraction, live bacteria, dead bacteria, dry bacteria or culture of Lactobacillus plantarium of the present invention as an active ingredient, and may further include an excipient or a carrier. The culture includes a culture solution itself cultured in a liquid medium, a filtrate (centrifuged supernatant) from which the strain is removed by filtration or centrifugation of the culture solution. The content of Lactobacillus plantarium in the composition may vary depending on the use and formulation of the composition.
상기 약학적 조성물은 병원성 세균의 감염증의 치료 또는 예방할 수 있는 조성물을 말하며 상기 병원성 세균은 스타필로코코스 에우리우스(Staphylococcus aureus), 대장균(E.coli), 바실러스 세레우스(B.cereus), 살모넬라 타이피뮤림(Salmonella typimurium), 살모넬라 콜레라수이스(Salmonella choleraesuis), 여시니아 엔테로콜리티카(Yersinia enterocolitica) 및 리스테리아 모노사이토게네스(Listeria monocytogenes)로 이루어진 군에서 선택된 하나 이상의 균을 말하며 상기 감염증은 상기 병원성 세균의 감염으로 인한 모든 질병을 포함하며 이에 한정되지는 않지만 구체적으로 식중독, 피부의 화농·중이염·방광염 등 화농성 질환을 말한다.The pharmaceutical composition refers to a composition capable of treating or preventing an infectious disease of a pathogenic bacterium, and the pathogenic bacterium is Staphylococcus aureus, E. coli, B. cereus, Salmonella thai. Refers to one or more fungi selected from the group consisting of Salmonella typimurium, Salmonella choleraesuis, Yersinia enterocolitica and Listeria monocytogenes. Including but not limited to all diseases caused by bacterial infections specifically refers to purulent diseases such as food poisoning, purulent, otitis media and cystitis of the skin.
본 발명에 따른 정장용, 생균제, 항균용 또는 약학적 조성물은 다양한 제형과 방법으로 제조 및 투여될 수 있다. 예를 들어, 락토바실러스 플란타륨 또는 이의 배양물을 약제학적 분야에서 통상적으로 사용하는 담체 및 향료와 혼합하여 정제(tablet), 트로키(troche), 캡슐(capsule), 엘릭실(elixir), 시럽(syrup), 산제(powder), 현탁제(suspension) 또는 과립제(granule) 등의 형태로 제조 및 투여될 수 있다. 상기 담체로는 결합제, 활탁제, 붕해제, 부형제, 가용화제, 분산제, 안정화제, 현탁화제 등을 사용할 수 있다. 투여방식은 경구, 비경구 또는 도포법을 사용할 수 있으나, 바람직하게는 경구 투여하는 것이 바람직하다. 또한, 투여용량은 체내에서 활성성분의 흡수도, 불활성율 및 배설속도, 피투여자의 연령, 성별, 상태 등에 따라 적절히 선택할 수 있다.Formal, probiotic, antimicrobial or pharmaceutical compositions according to the invention can be prepared and administered in a variety of formulations and methods. For example, Lactobacillus plantarium or its culture may be mixed with carriers and flavorings commonly used in the pharmaceutical arts for tablets, troches, capsules, elixirs, It may be prepared and administered in the form of syrup, powder, suspension or granule. As the carrier, a binder, a lubricant, a disintegrant, an excipient, a solubilizer, a dispersant, a stabilizer, a suspending agent and the like can be used. The mode of administration may be oral, parenteral or application, but preferably oral administration. In addition, the dosage may be appropriately selected depending on the absorbency, inactivation rate and excretion rate of the active ingredient in the body, age, sex, condition, etc. of the recipient.
또한, 본 발명에 따른 사료용 조성물은 발효사료, 배합사료, 펠렛형태 및 사일레지(silage) 등의 형태로 제조될 수 있다. 상기 발효사료는 본 발명의 락토바실러스 플란타륨과 여러 가지 미생물 균 또는 효소들을 첨가함으로써 유기물을 발효시켜 제조될 수 있으며, 상기 배합 사료는 여러 종류의 일반사료와 본 발명의 락토바실러스 플란타륨을 혼합하여 제조될 수 있다. 펠렛 형태의 사료는 상기 발효사료 또는 배합사료를 펠렛기로 제형화하여 제조될 수 있으며, 사일레지는 청예사료를 본 발명에 따른 락토바실러스 플란타륨으로 발효시킴으로서 제조될 수 있다.In addition, the feed composition according to the invention can be prepared in the form of fermented feed, compound feed, pellet form and silage (silage) and the like. The fermented feed may be prepared by fermenting an organic material by adding Lactobacillus plantarium of the present invention and various microorganisms or enzymes, and the blended feed may include various kinds of general feed and the Lactobacillus plantarium of the present invention. It can be prepared by mixing. The feed in pellet form may be prepared by formulating the fermented feed or blended feed into a pellet machine, and the silage may be prepared by fermenting the green feed with the Lactobacillus plantarium according to the present invention.
본 발명에 따른 락토바실러스 플란타륨 또는 이의 배양물은 김치, 음료, 이유식, 유제품 등의 식품에 대한 식품첨가제로 사용될 수 있다. 아울러, 본 발명의 락토바실러스 플란타륨은 발효식품의 제조를 위한 스타터(starter)로 사용될 수 있다. 상기 발효식품은 치즈, 김치, 발효생식제품 등을 포함한다. 본 발명의 락토바실러스 플란타륨을 이용한 발효식품은 당업계에 공지된 통상의 방법에 따라 제조될 수 있다. 예컨대, 현미와 율무 등의 곡류 분말에 본 발명에 따른 락토바실러스 플란타륨 또는 이를 포함하는 2 ~ 3종의 혼합 유산균을 처리하여 적정 온도에서 발효시킨 후, 백태, 찹쌀, 수수 등의 다양한 농산물을 영양적인 균형과 기호성이 우수하도록 적절히 배합하여 발효 생식제품을 제조할 수 있다. 특히 본 발명에 따른 락토바실러스 플란타륨은 김치를 제조하는데 사용할 수 있다. 바람직하게는 소금으로 절인 배추에 고춧가루, 마늘, 생강, 대파, 무채, 설탕과 같은 일반적인 김치 양념들을 혼합한 후, 본 발명의 락토바실러스 플란타륨의 배양물을 첨가하여 김치를 제 조할 수 있다. 상기 본 발명의 락토바실러스 플란타륨의 배양물은 김치 전체 중량에 대하여 0.1 ~ 5 중량% 로 첨가하는 것이 바람직하며, 1 중량% 로 첨가하는 것이 가장 바람직하다.Lactobacillus plantarium or its culture according to the present invention can be used as a food additive for food such as kimchi, beverages, baby food, dairy products. In addition, the Lactobacillus plantarium of the present invention can be used as a starter (starter) for the production of fermented food. The fermented foods include cheese, kimchi, fermented reproductive products and the like. Fermented foods using the Lactobacillus plantarium of the present invention can be prepared according to conventional methods known in the art. For example, by treating the grain powder such as brown rice and yulmu and the Lactobacillus plantarium according to the present invention or two to three kinds of mixed lactic acid bacteria containing the same and fermented at an appropriate temperature, various agricultural products such as white rice, glutinous rice, sorghum Fermented reproductive products can be prepared by properly formulating for excellent nutritional balance and palatability. In particular, the Lactobacillus plantarium according to the present invention can be used to prepare kimchi. Preferably, salted cabbage is mixed with common kimchi seasonings such as red pepper powder, garlic, ginger, leek, radish, and sugar, and then, kimchi may be prepared by adding a culture of the Lactobacillus plantarium of the present invention. The culture of the Lactobacillus plantarium of the present invention is preferably added at 0.1 to 5% by weight, and most preferably at 1% by weight based on the total weight of kimchi.
본 발명에 따른 락토바실러스 플란타륨은 통상적인 락토바실러스 속 미생물의 배양방법에 의해 대량으로 배양할 수 있다. 배양배지로는 탄소원, 질소원, 비타민 및 미네랄로 구성된 배지를 사용할 수 있으며, 예컨대, MRS(Man-Rogosa-Sharp)배지 또는 배추즙 배지를 사용할 수 있다. 상기 배추즙 배지는 절임배추를 분쇄하고 착즙한 후, 멸균하여 사용할 수 있다. 미생물의 배양은 통상의 락토바실러스 미생물의 배양 조건상에서 가능하며, 예컨대 25 ℃ 내지 37 ℃에서 18 시간 내지 48 시간 정도 배양할 수 있으며, 보다 바람직하게는 37 ℃에서 20시간 정도 배양할 수 있다. 배양액 중의 배양 배지를 제거하고 농축된 균체만을 회수하기 위해 원심분리 또는 여과 과정을 거칠 수 있으며, 이러한 단계는 당업자가 필요에 따라 수행할 수 있다. 농축된 균체는 통상적인 방법에 따라 냉동(frozen)하거나 또는 냉동건조(lyophilized)하여 그 활성을 잃지 않도록 보존할 수 있다.The Lactobacillus plantarium according to the present invention can be cultured in large quantities by a conventional method for culturing Lactobacillus sp. As the culture medium, a medium consisting of a carbon source, a nitrogen source, vitamins, and minerals may be used. For example, MRS (Man-Rogosa-Sharp) medium or Chinese cabbage juice medium may be used. The cabbage juice medium can be used after crushing and juice pickled cabbage, sterilized. Cultivation of the microorganism is possible under the culture conditions of the common Lactobacillus microorganisms, for example, can be cultured for 18 hours to 48 hours at 25 ℃ to 37 ℃, more preferably can be cultured at 37
이상 살펴본 바와 같이, 본 발명의 신규한 김치 유산균인 락토바실러스 플란타륨 DSR 330은 병원성 세균의 생육을 억제하는 활성이 있고 내산성, 내염성, 내담즙성 및 항생제 내성이 우수한 특징이 있다. 따라서 본 발명의 유산균은 정장용, 생균제, 항균용, 사료용, 식품첨가용, 약학적 조성물 및 발효식품의 제조에 다양하게 이용될 수 있다. 특히, 본 발명에 따른 락토바실러스 플란타륨 DSR 330을 김치 발효를 위한 스타터로 사용하여 제조하는 경우, 좋은 김치 맛을 오래 유지할 수 있고 김치에 기능성을 부가할 수 있을 뿐만 아니라, 병원성 세균으로 인한 감염증의 치료 및 예방에 효과적이다.As described above, the novel kimchi lactic acid bacterium of the present invention, Lactobacillus plantarium DSR 330, has the activity of inhibiting the growth of pathogenic bacteria and is characterized by excellent acid resistance, salt resistance, bile resistance and antibiotic resistance. Therefore, the lactic acid bacteria of the present invention can be used in various forms for the preparation of formal, probiotic, antibacterial, feed, food additives, pharmaceutical compositions and fermented foods. In particular, when using the Lactobacillus plantarium DSR 330 according to the invention as a starter for kimchi fermentation, not only can maintain a good kimchi taste and add functionality to kimchi, but also infectious diseases caused by pathogenic bacteria Effective in the treatment and prevention of
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시 예에 한정되는 것은 아니다.However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.
<실시예 1><Example 1>
락토바실러스 플란타륨 균주의 분리Isolation of Lactobacillus Plantarium Strains
<1-1> 김치로부터 유산균의 분리<1-1> Isolation of Lactic Acid Bacteria from Kimchi
통상적인 김치 제조방법으로 제조된 김치 20 종을 선택하고, 상기 김치를 유산균 분리 김치시료로 사용하였다. 상기 김치시료를 0.85 % 식염수로 10 배 희석하였고, 0.1 ㎖씩 MRS 아가 배지(MRS 아가, 디프코(Difco.); 박토 펩톤 10 g, 소고기추출물 10 g, 효모추출물 5 g, 글루코스 20 g, 트윈 801 g, 구연산 2 g, 제2 인산칼륨 2 g, 초산나트륨 5 g, 황산망간 0.1 g, 황산마그네슘 0.05 g, 아가 15 g/증류수 1 ℓ)플레이트에 접종한 후, 유리막대로 도말하였다. 이후, 플레이트를 25 ℃의 항온 배양기에서 2일 동안 배양하였다. 생성된 각각의 콜로니를 MRS 아가 플레이트에 획선 접종하였고, 25 ℃에서 2일 동안 배양하여 총 200 개의 유산균 콜로니를 분리하였다.20 kimchi prepared by the conventional kimchi production method was selected, and the kimchi was used as lactic acid bacteria isolated kimchi sample. The kimchi sample was diluted 10-fold with 0.85% saline, and 0.1 ml each of MRS agar medium (MRS agar, Difco .; 10 g of Bakto peptone, 10 g of beef extract, 5 g of yeast extract, 20 g of glucose, twin 801 g, citric acid 2 g, dibasic potassium phosphate 2 g, sodium acetate 5 g, manganese sulfate 0.1 g, magnesium sulfate 0.05 g, agar 15 g / distilled water 1 L) plate was inoculated and plated with a glass rod. The plates were then incubated for 2 days in a 25 ° C. incubator. Each colony produced was inoculated into MRS agar plates and incubated at 25 ° C. for 2 days to separate a total of 200 lactic acid bacteria colonies.
<1-2> <1-2> 병원성세균의Pathogenic bacteria 생육을 억제하는 유산균의 분리 Isolation of Lactic Acid Bacteria Suppressing Growth
상기 실시예 <1-1>에서 분리된 200개의 유산균들 중에서 병원성세균의 생육을 저해하는 유산균을 선발하기 위하여, 먼저 병원성세균 4종 스타필로코코스 에우리우스(Staphylococcus aureus KCCM 12214), 대장균 KCCM 11234(E.coli KCCM 11234), 바실러스 세레우스 KCCM 11774(B.cereus KCCM 11774) 및 살모넬라 타이피뮤림 KCCM 40253(Salmonella typimurium KCCM 40253)을 뉴트리언트 배지(박토 펩톤 5.0 g, 소고기추출물 1.0 g, 효모추출물 2.0 g, 염화나트륨 5.0 g, 아가 15 g/증류수 1ℓ)에 접종하여 37 ℃, 24 시간 배양하였다. 상기 배양된 균체들을 배지로부터 긁어모아 인산완충액(PBS, pH 7.4)으로 2회 세척하고 20 % 글리세롤(glycerol)에 현탁시켜 -20 ℃에 보관하였고, 상기 실시예 <1-1>에서 분리한 200개의 유산균 콜로니들은 MRS 액체배지에 접종하여 37 ℃에서 24 시간 배양한 후, 원심 분리하여 균체에 10% skim milk 에 현탁하여 -20 ℃에 보관하였다.In order to select lactic acid bacteria that inhibit the growth of pathogenic bacteria among the 200 lactic acid bacteria isolated in Example <1-1>, first, four pathogenic bacteria Staphylococcus aureus KCCM 12214, E. coli KCCM 11234 ( E.coli KCCM 11234), Bacillus cereus KCCM 11774 (B.cereus KCCM 11774) and Salmonella typhimurium KCCM 40253 (Salmonella typimurium KCCM 40253) were prepared in a nutrient medium (5.0 g of Bacterium peptone, 1.0 g of beef extract, 2.0 g of yeast extract). g, sodium chloride 5.0 g, agar 15 g / distilled water 1 L) and incubated for 24 hours at 37 ℃. The cultured cells were scraped from the medium, washed twice with phosphate buffer (PBS, pH 7.4), suspended in 20% glycerol, and stored at -20 ° C. The 200 was separated in Example <1-1>. Dog lactic acid colonies were inoculated in MRS liquid medium and incubated at 37 ° C. for 24 hours, followed by centrifugation, suspended in 10% skim milk, and stored at −20 ° C.
이후, 뉴트리언트 한천배지(Nutrient agar)에 병원성세균을 1 % 접종하여 20 분간 건조한 후, 여기에 디스크 페이퍼를 올려놓고 상기 200개의 각 유산균 배양 상등액 50 ㎕를 적하시키고 37 ℃에서 24 시간 동안 배양하여 억제 환을 형성하는 유산균 중 가장 우수한 균주를 1차 선발하였다. 이후, 상기 1차 선발된 균주들을 상기와 같은 방법으로 다시 2차 선발하여 최종적으로 병원성 세균의 생육을 가장 우수하게 억제하는 DSR 330을 선발하였다(도 2 참조).Subsequently, inoculate 1% of the pathogenic bacteria in Nutrient agar and dry for 20 minutes. Then, put the disc paper on it and add 50 μl of each of the 200 lactic acid bacteria culture supernatants, and incubate at 37 ° C. for 24 hours. The best strain among the lactic acid bacteria forming the inhibitory ring was selected first. Thereafter, the first selected strains were selected again in the same manner as above, and finally DSR 330 was selected to best inhibit the growth of pathogenic bacteria (see FIG. 2).
<1-3> 내산성 테스트<1-3> acid resistance test
상기 실시예 <1-2>에서 분리된 병원성세균의 생육을 가장 우수하게 억제하는 DSR 330 유산균을 염산을 이용하여 pH 2.5, 3.0, 3.5, 4.0, 4.5, 5로 조정한 MRS 브로스(MRS 브로스, Difco.; 박토 펩톤 10 g, 소고기추출물 10 g, 효모추출물 5 g, 글루코스 20 g, 트윈 801 g, 구연산 2 g, 제2인산칼륨 2 g, 초산나트륨 5 g, 황산망간 0.1 g, 황산마그네슘 0.05 g/증류수 1ℓ) 10 ㎖에 각각 접종하였다. 이후, 37 ℃에서 2 시간 동안 배양하면서 생균수를 조사하였다.MRS broth adjusted to pH 2.5, 3.0, 3.5, 4.0, 4.5, 5 using DSR 330 lactic acid bacteria that best inhibit the growth of pathogenic bacteria isolated in Example <1-2> using hydrochloric acid (MRS broth, Difco .; 10 g of Bakto peptone, 10 g of beef extract, 5 g of yeast extract, 20 g of glucose, 801 g of citric acid, 2 g of citric acid, 2 g of potassium diphosphate, 5 g of sodium acetate, 0.1 g of manganese sulfate, 0.05 g of
그 결과, 상기 선별된 균주는 pH 2.5 ~ 5에서 생육이 활발하고, 특히 pH 2.5에서도 90 % 이상 생존하며, pH 3에서 약 95 % 이상의 생존율을 나타내어 내산성이 강한 것으로 나타났다(도 3 참조).As a result, the selected strains were actively grown at pH 2.5-5, particularly survived 90% or more even at pH 2.5, showed a viability of about 95% or more at pH 3 (see Fig. 3).
<1-4> 내염성 테스트<1-4> flame resistance test
상기 실시예 <1-2>에서 분리된 DSR 330 유산균을 염화나트륨(NaCl)로 2, 5, 8, 10 및 15 %로 조정한 MRS 브로스 10 ㎖에 각각 접종하였다. 이후, 37 ℃에서 2시간 배양하면서 상기 염농도에서 균주의 생육을 관찰하였다. 그 결과, 상기 선별된 균주는 염화나트륨 2~15 %에서 생육이 활발하며, 특히 염화나트륨 15 %에서도 97 % 이상의 생존율을 나타내었다(도 4 참조).DSR 330 lactic acid bacteria isolated in Example <1-2> were inoculated into 10 ml of MRS broth adjusted to 2, 5, 8, 10 and 15% with sodium chloride (NaCl), respectively. Then, the growth of the strain was observed at the salt concentration while incubating for 2 hours at 37 ℃. As a result, the selected strains were actively grown at 2-15% of sodium chloride, and especially showed a survival rate of 97% or more even at 15% of sodium chloride (see FIG. 4).
<1-5> 내담즙성 테스트<1-5> Bile Resistance Test
상기 실시예 <1-2>에서 분리된 DSR 330 유산균을 옥스갈(oxgall)로 0.3, 0.5, 1 및 3 %로 조정한 MRS 브로스 10 ㎖에 각각 접종하였다. 이후, 37 ℃에서 2 시간 배양하면서 상기 인공 담즙 농도에서의 균주의 생육을 관찰하였다. 그 결과, 상기 선별된 균주는 옥스갈(oxgall) 0.3 ~ 3.0 %에서 생육이 활발하며, 특히 옥스갈(oxgall) 3 %에서도 95 % 이상의 생존율을 나타내었다(도 5 참조).DSR 330 lactic acid bacteria isolated in Example <1-2> were inoculated into 10 ml of MRS broth adjusted to 0.3, 0.5, 1 and 3% with oxgall, respectively. Thereafter, the growth of the strain at the artificial bile concentration was observed while incubating at 37 ° C for 2 hours. As a result, the selected strains were actively growing at 0.3 to 3.0% of oxgall, and particularly showed a survival rate of 95% or more even at 3% of oxgall (see FIG. 5).
<1-6> 항생제 내성 테스트<1-6> Antibiotic Resistance Test
상기 실시예 <1-2>에서 분리된 DSR 330 유산균을 MRS 고체배지에 접종하고, 항생제가 포함된 필터(직경 6 mm)를 올려놓고 24시간 배양하여 항생제에 의한 형성된 억제 환의 크기를 측정하였다. 억제 환의 크기가 작을수록 항생제에 대한 내성이 크다는 것을 의미한다. 하기 표 1은 DSR 330에 대한 항생제 내성정도를 나타낸 것이다.The DSR 330 lactic acid bacteria isolated in Example <1-2> were inoculated into MRS solid medium, placed on a filter containing antibiotics (6 mm in diameter) and incubated for 24 hours to determine the size of the inhibitory ring formed by the antibiotic. Smaller inhibitory rings mean more resistance to antibiotics. Table 1 below shows the degree of antibiotic resistance to DSR 330.
상기 표 1에 기재된 것과 같이 본 발명의 DSR 330 균주는 항생제 내성이 우수하여 항생제와 함께 정장용, 생균제, 사료용, 식품첨가용, 항균용, 약학적 조성물 및 발효식품에 사용하더라도 그 활성이 유지되어 유용하게 이용될 수 있음을 알 수 있었다.As shown in Table 1, the DSR 330 strain of the present invention is excellent in antibiotic resistance, and its activity is maintained even when used in formal, probiotic, feed, food additive, antibacterial, pharmaceutical compositions and fermented foods with antibiotics. It can be seen that it can be used.
<1-7> 항균력 테스트<1-7> antibacterial activity test
상기 실시예 <1-2>에서 분리된 DSR 330 유산균을 항균력 테스트를 위해 MRS 브로스에 3 차 계대 배양하고, 뉴트리언트 한천배지(Nutrient agar)에 병원성세균 스타필로코코스 에우리우스(Staphylococcus aureus KCCM 12214), 대장균(E.coli KCCM 11234), 바실러스 세레우스(B.cereus KCCM 11774) 및 살모넬라 타이피뮤림(Salmonella typimurium KCCM 40253), 살모넬라 콜레라수이스(Salmonella choleraesuis KCCM40763), 바실러스 세레우스(Bacillus cereus KCCM11204), 여시니아 엔테로콜리티카(Yersinia enterocolitica KCCM 41657), 스타필로코코스 에우리우스(Staplyococcus aureus KCCM 11335), 리스테리아 모노사이토게네스(Listeria monocytogenes KCCM4307)의 1 %를 접종하여 20 분간 건조한 후, 여기에 디스크 페이퍼를 올려놓고 상기 DSR 330 유산균의 배양 상등액 50 ㎕를 적하시켜 37 ℃에서 24 시간 동안 배양하여 억제 환의 크기를 측정하여 하기 표 2에 기재하였다.The DSR 330 lactic acid bacteria isolated in Example <1-2> were subcultured in an MRS broth for three times for antibacterial activity test, and the pathogenic bacterium Staphylococcus aureus KCCM 12214 on nutritious agar medium (Nutrient agar). , E. coli KCCM 11234, B.cereus KCCM 11774 and Salmonella typimurium KCCM 40253, Salmonella choleraesuis KCCM40763, Bacillus cereus KCCM204 cereus Inoculated with 1% of Yersinia enterocolitica KCCM 41657, Staphylocococcus aureus KCCM 11335, Listeria monocytogenes KCCM4307 and dried for 20 minutes. Put the 50 μl of the culture supernatant of the DSR 330 lactic acid bacteria dropping and incubated for 24 hours at 37 ℃ to measure the size of the inhibitory ring Groups are shown in Table 2.
상기 표 2에 기재된 것과 같이 본 발명의 DSR 330 균주는 상기 병원성 세균에 대한 항균력이 우수하며 특히 여시니아 엔테로콜리티카, 리스테리아 모노사이토게네스 및 바실러스 세레우스 KCCM 11774 등의 병원성 세균에 대해서는 억제 환의 크기가 20 mm을 넘어 우수한 항균력을 가지고 있어, 상기 병원성세균에 대한 항균제로 유용하게 이용될 수 있음을 알 수 있었다.As shown in Table 2, the DSR 330 strain of the present invention is excellent in antimicrobial activity against the pathogenic bacteria, especially the size of the inhibitory ring for pathogenic bacteria such as Yexinia enterocylica, Listeria monocytogenes and Bacillus cereus KCCM 11774. Has an excellent antibacterial activity over 20 mm, it can be seen that it can be usefully used as an antimicrobial agent for the pathogenic bacteria.
<1-8> 선별된 유산균의 동정<1-8> Identification of Selected Lactic Acid Bacteria
a. 버지스의 분류 세균학 매뉴얼에 따른 분석a. Analysis according to Burgess's classification bacteriology manual
상기 실시예 <1-2>에서 선별된 유산균을 단일 콜로니로 분리한 후, 버지스의 분류 세균학 매뉴얼(Bergy's manual of systematic bacteriology)에 준하여 형태학적 및 생화학적 특성을 조사하였고, 그람 염색을 수행하였다. 그 결과, 상기 분리된 균주는 그람 양성 균주이며 간균의 형태를 갖고 있음을 확인할 수 있었다(표 3 및 도 6 참조).After lactic acid bacteria selected in Example <1-2> were separated into single colonies, morphological and biochemical properties were investigated according to Burges' manual of systematic bacteriology, and gram staining was performed. As a result, it was confirmed that the isolated strain is a Gram-positive strain and has a form of bacilli (see Table 3 and FIG. 6).
b. API 시스템을 이용한 분석b. Analysis using API system
이후, 상기 균주는 API 시스템(API system; La Balme-les-Grottes, France)으로 동정하였다. 우선, 멸균 백금이로 균 콜로니를 각각 취한 후 멸균 증류수 2 ㎖에 부유시켰다. 다시 상기 균액을 멸균 증류수 5 ㎖에 API 50CH 키트(BioMerieux, France)에서 제공되는 맥팔란드 표준 용액 No.2(MccFaland Standard Solution No.2)의 농도로 균액을 부유시켰다. 상기 부유액을 API 50CH 키트의 액체배지에 첨가하여 균질화시킨 후, API 50CH 키트의 50개 각 튜브에 200 ㎕씩 접종하였다. 미네랄 오일로 튜브 위를 엎어준 후, 30 ℃에서 48 시간 동안 배양시켰다. 상기 배양액을 API 시스템으로 분석하여 49종의 탄수화물 발효패턴을 확인한 후, 이 결과를 ATB 동정 컴퓨터 시스템에 입력하여 동정하였다.Thereafter, the strain was identified by an API system (La Balme-les-Grottes, France). First, bacteria colonies were taken with sterile platinum and then suspended in 2 ml of sterile distilled water. Again, the bacteria solution was suspended in 5 ml of sterile distilled water at the concentration of McFalland Standard Solution No. 2 (MccFaland Standard Solution No. 2) provided by the API 50CH kit (BioMerieux, France). The suspension was added to the liquid medium of the API 50CH kit for homogenization, and then 200 μl of each 50 tubes of the API 50CH kit was inoculated. After spilling on the tube with mineral oil, it was incubated for 48 hours at 30 ℃. The culture was analyzed by the API system to confirm 49 carbohydrate fermentation patterns, and the results were identified by inputting the ATB identification computer system.
그 결과, 상기 실시예 <1-2>에서 선별된 DSR 330 유산균은 하기 표 4의 탄수화물 발효패턴을 갖고 있는 락토바실러스 속에 속하는 균주인 것으로 판명되었다.As a result, the DSR 330 lactic acid bacteria selected in Example <1-2> were found to be a strain belonging to the genus Lactobacillus having a carbohydrate fermentation pattern of Table 4 below.
c. 16S rDNA 염기서열 분석c. 16S rDNA Sequencing
당업계에 공지된 통상적인 방법에 따라 상기 선별된 유산균들의 16S rDNA의 염기서열을 분석하였다. 그 결과, 상기 DSR 330번 유산균의 16S rDNA 염기서열(서열번호 1)은 락토바실러스 플란타륨의 16S rDNA 염기서열과 99 % 동일함을 알 수 있었다(도 1 참조).The nucleotide sequence of 16S rDNA of the selected lactic acid bacteria was analyzed according to a conventional method known in the art. As a result, the 16S rDNA base sequence (SEQ ID NO: 1) of the lactic acid bacteria DSR 330 was found to be 99% identical to the 16S rDNA base sequence of Lactobacillus plantarium (see Fig. 1).
따라서, 본 발명자들은 DSR 330번 유산균을 "락토바실러스 플란타륨 DSR 330"으로 명명하고 이를 한국미생물보존센터(Korean Culture Center of Microorganisms)에 2007년 8월 10일자로 기탁하였다(기탁번호: KFCC-11393P). Therefore, the present inventors named DSR 330 lactic acid bacteria as "Lactobacillus plantarium DSR 330" and deposited it on August 10, 2007 at the Korean Culture Center of Microorganisms (Accession No .: KFCC- 11393P).
<실시예 2><Example 2>
본 발명의 유산균을 이용한 김치 제조Kimchi production using the lactic acid bacteria of the present invention
배추를 각각 소금으로 절여 배추의 염도가 2.3 %가 되도록 하였다. 절인 배추(82.5 중량%)에 고춧가루(2.5 중량%), 마늘(2 중량%), 생강(0.5 중량%), 대파(2 중량%), 무채(9 중량%), 설탕(0.5 중량%)의 김치 양념을 혼합하였다. 이후, 스타터로 본 발명의 락토바실러스 플란타륨 DSR 330을 김치 전체 중량에 대하여 1 중량%(약 1×105 균주)로 각각 첨가하였다. 이때, 음성 대조군에는 스타터 유산균을 첨가하지 않았다. 이후, 제조된 각 김치를 10 ℃에서 6일간 숙성시켰다.The cabbages were each salted so that the salinity of the cabbages was 2.3%. Pickled Chinese cabbage (82.5% by weight) of red pepper powder (2.5% by weight), garlic (2% by weight), ginger (0.5% by weight), leek (2% by weight), radish (9% by weight), sugar (0.5% by weight) Kimchi seasoning was mixed. Then, as a starter, the Lactobacillus plantarium DSR 330 of the present invention was added at 1% by weight (about 1 × 10 5 strains) based on the total weight of kimchi, respectively. At this time, starter lactic acid bacteria were not added to the negative control. Then, each kimchi prepared was aged for 6 days at 10 ℃.
<실험예 1>Experimental Example 1
제조된 김치의 산도 및 유산균 수 측정Measurement of Acidity and Lactic Acid Bacteria in Prepared Kimchi
<1-1> 산도 측정<1-1> pH measurement
상기 실시예 <2>에서 제조된 각 김치를 대상으로 산도를 측정하였다. 10 ℃에서 10일 동안 숙성시킨 각 김치 100 g을 마쇄한 후 거즈로 여과하여 김치액을 제조하였다. 이후, 김치의 숙성된 상태를 비교하기 위하여 각 김치의 산도를 측정하였다. 산도는 NaCl 적정법을 이용하여 측정하였다. 각 김치로부터 김치즙액을 제조한 후, 김치즙액 5 ㎖의 pH를 측정하였다. 이후, 0.1N NaOH를 적정하여 pH 8.2 가 되는 시점의 0.1N NaOH의 첨가량을 계산하여 하기의 수학식 1로 산도(%)를 구하여, 그 결과를 하기 표 5에 기재하였다.Acidity was measured for each kimchi prepared in Example <2>. Kimchi liquid was prepared by grinding 100 g of each kimchi aged at 10 ° C. for 10 days and then filtering with gauze. Then, the acidity of each kimchi was measured to compare the matured state of kimchi. Acidity was measured using NaCl titration. After preparing kimchi juice from each kimchi, the pH of 5 ml of kimchi juice was measured. Then, 0.1N NaOH was titrated to calculate the addition amount of 0.1N NaOH at the time of pH 8.2, and the acidity (%) was calculated by the following
* 1N NaOH 인자 = 1 * 1N NaOH factor = 1
그 결과, 상기 표 5에서 보는 바와 같이, 락토바실러스 플란타륨 DSR 330 균주를 이용하여 제조된 김치는 스타터를 사용하지 않고 제조된 김치에 비해 산도가 비교적 낮아 상기 유산균은 김치의 발효 후반부에 산도를 서서히 증가시켜 적숙기를 연장함으로서 김치 품질을 향상 시킬 수 있음을 알 수 있었다. As a result, as shown in Table 5, kimchi prepared using the Lactobacillus plantarium DSR 330 strain has a relatively low acidity compared to kimchi prepared without the use of a starter. It was found that the kimchi quality could be improved by gradually increasing the ripening season.
<1-2> 김치의 유산균 수 측정<1-2> Measurement of Lactic Acid Bacteria in Kimchi
상기 실시예 <2>에서 제조된 각 김치의 유산균 수를 측정하였다. 10 ℃에서 6일 동안 숙성시킨 각 김치를 0.85 % 식염수로 10배 희석하고 MRS 아가 배지(MRS 아가, 디프코(Difco.); 박토 펩톤 10 g, 소고기 추출물 10 g, 효모 추출물 5 g, 글루코스 20 g, 트윈 80 1 g, 구연산 2 g, 제2 인산칼륨 2 g, 초산나트륨 5 g, 황산망간 0.1 g, 황산마그네슘 0.05 g, 아가 15 g/증류수 1 ℓ) 플레이트에 상기 김치 희석액 0.1 ㎖을 접종한 후, 유리막대로 도말하였다. 상기 김치 희석액이 도말된 각 아가 플레이트를 27 ℃의 항온배양기에서 12 일 동안 배양한 후 생성된 집락의 수를 각각의 균수로 계수하여 그 결과를 표 6에 기재하였다.The number of lactic acid bacteria of each kimchi prepared in Example <2> was measured. Each kimchi aged for 6 days at 10 ° C. was diluted 10-fold with 0.85% saline, and MRS agar medium (MRS agar, Difco .; 10 g of Bakto peptone, 10 g of beef extract, 5 g of yeast extract, glucose 20 g, Tween 80 g, citric acid 2 g, dibasic potassium phosphate 2 g, sodium acetate 5 g, manganese sulfate 0.1 g, magnesium sulfate 0.05 g, agar 15 g / distilled water 1 L) plate was inoculated with 0.1 ml of the kimchi dilution After that, the glass plate was smeared. Each agar plate coated with the kimchi dilution solution was incubated in an incubator at 27 ° C. for 12 days, and the number of colonies produced was counted by each number of bacteria, and the results are shown in Table 6.
그 결과, 상기 표 6에서 보는 바와 같이 본 발명의 유산균을 첨가하여 제조된 김치에서 스타터를 첨가하지 않고 제조된 김치에 비해 총 유산균 수가 현저하게 증가된 것을 확인할 수 있었다.As a result, as shown in Table 6, it was confirmed that the total number of lactic acid bacteria was significantly increased compared to kimchi prepared without adding the starter in the kimchi prepared by adding the lactic acid bacteria of the present invention.
<실험예 2>Experimental Example 2
제조된 김치의 관능 검사Sensory test of the manufactured kimchi
상기 실시예 <2>에서 제조된 각 김치의 관능검사를 수행하였다. 10 ℃에서 6일 동안 숙성시킨 후, 4 ℃에서 보관한 지 2일째 되는 각 김치에 대하여 훈련된 검사요원 10명이 관능검사를 수행하였다. 5점을 만점으로 기호도 척도법에 의해 실시하였으며, 유의성 검증은 t-테스트에 의해 실시하였다. 그 결과를 하기 표 7에 나타내었다. The sensory test of each kimchi prepared in Example <2> was performed. After ripening for 6 days at 10 ℃, 10 trained test personnel for each
그 결과, 상기 표 7에서 보는 바와 같이, 본 발명의 유산균을 첨가하여 제조된 김치가 스타터를 첨가하지 않고 제조된 김치에 비해 전반적으로 관능 특성이 우수한 것으로 평가되었다.As a result, as shown in Table 7, the kimchi prepared by adding the lactic acid bacterium of the present invention was evaluated to have excellent overall sensory properties compared to kimchi prepared without adding a starter.
<실시예 3> <Example 3>
본 발명의 유산균을 이용한 동치미의 제조Preparation of Dongchimi Using Lactic Acid Bacteria of the Invention
무 및 배추를 소금으로 절여 배추의 염도가 4.0 %가 되도록 하였다. 상기 절인 배추(6 %)와 무(38 %)에 마늘(3 중량%), 생강(0.2 중량%), 포도당(5 중량%)등으로 구성된 동치미 양념을 혼합하였다. 이후, 스타터로 본 발명의 락토바실러스 플란타륨 DSR 330을 동치미 전체 중량에 대하여 1 중량%(약 1×105 균주)로 각각 첨가한 후 25 ℃에서 5일간 발효시켜 동치미를 제조하였다. 이때 스타터 유산균을 첨가하지 않은 경우를 음성대조군으로 하였다.The radish and cabbage were pickled with salt so that the salinity of the cabbage was 4.0%. The pickled cabbage (6%) and radish (38%) were mixed with Dongchimi seasoning consisting of garlic (3% by weight), ginger (0.2% by weight), glucose (5% by weight) and the like. Thereafter, the lactobacillus plantarium DSR 330 of the present invention was added as a starter to 1% by weight (about 1 × 10 5 strains), respectively, and then fermented at 25 ° C. for 5 days to prepare a copper tooth. At this time, the case where no starter lactic acid bacteria were added was used as a negative control group.
<실험예 3>Experimental Example 3
제조된 동치미의 산도 및 유산균 수 측정Determination of Acidity and Lactic Acid Bacteria in Prepared Dongchimi
<3-1> 산도 측정<3-1> pH measurement
상기 실시예 <3>에서 제조된 동치미 국물을 거즈로 여과하여 동치미액을 제조한 후, 동치미액 5 ㎖의 pH를 측정하고 실험예 <1-1>과 동일한 방법으로 산도를 계산하여 그 결과를 하기 표 8에 기재하였다.After preparing the Dongchimi solution by filtering the Dongchimi broth prepared in Example <3> with gauze, the pH of 5 mL of Dongchimi solution was measured and the acidity was calculated in the same manner as in Experimental Example <1-1>. It is listed in Table 8 below.
그 결과, 상기 표 8에서 보는 바와 같이, 본 발명의 유산균을 이용하여 제조된 동치미의 산도는 스타터를 이용하지 않고 제조된 동치미에 비해 산도가 빠르게 증가 하였다. 따라서 본 발명의 유산균은 동치미의 발효를 빠르게 유도하여 적정 산도를 나타냄을 확인할 수 있었다.As a result, as shown in Table 8, the acidity of the Dongchimi prepared using the lactic acid bacteria of the present invention, the acidity of the Dongchimi prepared without using a starter increased rapidly. Therefore, the lactic acid bacteria of the present invention was able to confirm that the fermentation of Dongchimi exhibited the proper acidity.
<3-2> 동치미의 유산균 수 측정<3-2> Measurement of Lactic Acid Bacteria in Dongchimi
상기 실시예 <3>에서 제조된 각 동치미를 0.85 % 식염수로 10배 희석하여 실험예 <1-2>와 동일한 방법으로 총 유산균수를 측정하고 그 결과를 표 9에 기재하였다.Each Dongchimi prepared in Example <3> was diluted 10-fold with 0.85% saline, and the total number of lactic acid bacteria was measured in the same manner as in Experimental Example <1-2>, and the results are shown in Table 9.
그 결과, 상기 표 9에서 보는 바와 같이, 본 발명의 유산균을 첨가하여 제조된 동치미에서 스타터를 첨가하지 않고 제조된 동치미에 비해 총 유산균 수가 증가된 것을 확인할 수 있었다.As a result, as shown in Table 9, it was confirmed that the total number of lactic acid bacteria was increased compared to the Dongchimi prepared without the starter in the Dongchimi prepared by adding the lactic acid bacteria of the present invention.
<3-3> 제조된 동치미의 항균력 측정<3-3> Antibacterial activity of the prepared Dongchimi
병원성 세균인 살모넬라 콜레라(Salmonella choleraesuis KCCM40763), 여시니아 엔테로콜리티카(Yersinia enterocolitica KCCM 41657), 리스테리아 모노사이토게네스(Listeria monocytogenes KCCM4307), 스타필로코코스 에우리우스(Staphylococcus aureus KCCM 12214), 대장균(E.coli KCCM 11234), 살모넬라 타이피뮤림(Salmonella typimurium KCCM 40253), 바실러스 세레우스(B.cereus KCCM 11774)를 뉴트리언트 배지(박토 펩톤 5.0 g, 소고기추출물 1.0 g, 효모추출물 2.0 g, 염화나트륨 5.0 g, 아가 15 g/증류수 1 ℓ)에 접종하여 37 ℃, 24시간 배양한 후, 뉴트리언트 한천배지(Nutrient agar)에 접종하여 20 분간 건조한 후, 여기에 디스크 페이퍼를 올려놓고 상기 실시예 <3>에서 제조된 동치미액을 50 ㎕를 적하시키고 37 ℃에서 24 시간 동안 배양하여 억제 환을 측정하여 그 결과를 표 10에 기재하였다 Pathogenic bacteria Salmonella choleraesuis KCCM40763, Yersinia enterocolitica KCCM 41657, Listeria monocytogenes KCCM4307, Staphylococcus aureus coli 12214, E. coli coli KCCM 11234), Salmonella typimurium KCCM 40253, Bacillus cereus (B.cereus KCCM 11774) in a nutrient medium (5.0 g of Bacterium peptone, 1.0 g of beef extract, 2.0 g of yeast extract, 5.0 g of sodium chloride, 15 g of agar was inoculated in 1 l of distilled water, and incubated for 24 hours at 37 ° C., and then inoculated in Nutrient agar and dried for 20 minutes. 50 μl of the prepared Dongchimi solution was added dropwise and incubated at 37 ° C. for 24 hours to measure the inhibitory ring. The results are shown in Table 10 below.
상기 표 10에 기재된 것과 같이 본 발명의 DSR 330 균주를 이용하여 제조된 동치미는 상기 병원성 세균에 대한 항균력이 우수하며 특히 여시니아 엔테로콜리티카, 리스테리아 모노사이토게네스, 바실러스 세레우스 KCCM 11774 및 바실러스 세레우스 KCCM11204등의 병원성 세균에 대해서는 억제 환의 크기가 20 mm을 넘어 우수한 항균력을 가지고 있음을 알 수 있었다. Dongchimi prepared using the DSR 330 strain of the present invention as shown in Table 10 is excellent in the antimicrobial activity against the pathogenic bacteria, in particular Yexinia enterocholicica, Listeria monocytogenes, Bacillus cereus KCCM 11774 and Bacillus sere For pathogenic bacteria such as U.S. KCCM11204, it was found that the size of the inhibitory ring had an excellent antibacterial activity over 20 mm.
<제조예 1> <Manufacture example 1>
본 발명의 유산균을 이용한 사료용 조성물의 제조Preparation of a feed composition using the lactic acid bacteria of the present invention
본 발명의 락토바실러스 플란타륨 DSR 330 유산균을 2.0 % 글루코스, 1.0 % 펩톤, 1.0 % 효모추출물, 0.2 % 제이인산, 0.05 % 황산마그네슘 및 0.05 % 시스테인이 함유된 배지에 접종하여 37 ℃에서 2일 동안 호기적으로 배양하였다. 각 균주의 배양액과 부형제 탈지강을 1:1의 중량비로 단순 혼합한 후 40 ℃ 이하에서 건조시켰으며, 건조된 혼합물을 분쇄하여 사료용 조성물을 제조하였다. 이때 제조된 사료용 조성물은 본 발명의 유산균이 1×109 cfu/g 이상으로 포함되도록 하였다.Lactobacillus plantarium DSR 330 lactic acid bacteria of the present invention was inoculated in a medium containing 2.0% glucose, 1.0% peptone, 1.0% yeast extract, 0.2% diphosphate, 0.05% magnesium sulfate and 0.05% cysteine at 37 ° C for 2 days. While aerobic incubation. The culture medium and the excipient degreasing steel of each strain were simply mixed at a weight ratio of 1: 1, dried at 40 ° C. or less, and the dried mixture was ground to prepare a feed composition. At this time, the prepared feed composition was to be included as lactic acid bacteria of the
<제조예 2><Manufacture example 2>
본 발명의 유산균을 이용한 생균제 조성물의 제조Preparation of probiotic composition using lactic acid bacteria of the present invention
본 발명의 락토바실러스 플란타륨 DSR 330 유산균을 2.0 % 글루코스, 1.0 % 펩톤, 1.0 % 효모추출물, 0.2 % 제이인산, 0.05 % 황산마그네슘 및 0.05 % 시스테인이 함유된 배지에 접종하여 37 ℃에서 2 일 동안 호기적으로 배양하였다. 탈지강, 대두박, 옥분 및 당밀이 각각 3:1:1:1의 중량비로 혼합되어 들어 있는 고체 배양기에 상기 각 균주의 배양액을 10 중량%로 접종한 후, 여기에 물을 45 내지 60 중량%로 첨가하였다. 이를 40 ℃에서 3 일 동안 교반시키면서 혐기적으로 고체발효를 수행하여 생균제 조성물을 제조하였으며, 이때 제조된 생균제 조성물은 본 발명의 유산균이 1×109 cfu/g 이상으로 포함되도록 하였다.The Lactobacillus plantarium DSR 330 lactic acid bacteria of the present invention were inoculated in a medium containing 2.0% glucose, 1.0% peptone, 1.0% yeast extract, 0.2% diphosphate, 0.05% magnesium sulfate and 0.05% cysteine at 37 ° C. for 2 days. While aerobic incubation. After inoculating 10% by weight of the culture solution of each strain in a solid incubator containing skim steel, soybean meal, jade powder and molasses in a weight ratio of 3: 1: 1: 1, respectively, 45-60% by weight of water was added thereto. Was added. The probiotic composition was prepared by anaerobic solid fermentation while stirring at 40 ° C. for 3 days, and the probiotic composition thus prepared contained lactic acid bacteria of 1 × 10 9 cfu / g or more.
<제조예 3> <Manufacture example 3>
본 발명의 유산균을 이용한 식품첨가용 조성물의 제조Preparation of a food additive composition using the lactic acid bacteria of the present invention
본 발명의 락토바실러스 플란타륨 DSR 330 유산균을 각각 2.0 % 글루코스, 1.0 % 펩톤, 1.0 % 효모추출물, 0.2 % 제이인산 및 0.05 % 황산마그네슘, 0.05 % 시스테인 등이 함유된 배지에 접종하여 37 ℃에서 2 일간 호기적으로 배양하였다. 분유 또는 탈지유(skim milk) 및 전분 또는 유당을 1:1 중량비로 혼합한 혼합물에 상기 배양액을 60 중량%로 첨가한 후, 이를 -70℃ 이하에서 급속 냉동시킨 후, -60 ℃에서 36 시간 동안 동결 건조시켜 식품첨가용 조성물을 제조하였다. 이때, 동결건조시 수분 증발 효율을 높이기 위한 열판의 온도는 30 ℃로 하였으며, 이때 제조된 식품첨가용 조성물은 본 발명의 유산균이 1×109 cfu/g 이상으로 포함되도록 하였다.The Lactobacillus plantarium DSR 330 lactic acid bacteria of the present invention were inoculated in a medium containing 2.0% glucose, 1.0% peptone, 1.0% yeast extract, 0.2% diphosphate and 0.05% magnesium sulfate, 0.05% cysteine and the like at 37 ° C. Cultured aerobic for 2 days. 60% by weight of the culture solution was added to a mixture of milk powder or skim milk and starch or lactose in a 1: 1 weight ratio, which was then rapidly frozen at −70 ° C. or lower and then at −60 ° C. for 36 hours. Freeze drying to prepare a composition for food addition. At this time, the temperature of the hot plate to increase the water evaporation efficiency during lyophilization was 30 ℃, wherein the prepared food additive composition was to include the lactic acid bacteria of the
<< 제조예Production Example 4> 4>
본 발명의 유산균을 이용한 약학적 조성물의 제조Preparation of a pharmaceutical composition using the lactic acid bacteria of the present invention
상기 제조예 1, 2 및 3에서 얻어진 생균 조성물 분말을 각각 통상적인 방법에 따라 정제, 환제 및 캡슐제로 성형하여 약학조성물로 제조하였으며, 이때 제조된 조성물은 본 발명의 유산균이 1×109 cfu/g 이상으로 포함되도록 하였다.The probiotic composition powders obtained in Preparation Examples 1, 2, and 3 were each prepared in a pharmaceutical composition by molding into tablets, pills, and capsules according to a conventional method, wherein the prepared composition was lactic acid bacteria of 1 × 10 9 cfu / It was included more than g.
도 1은 본 발명의 유산균의 16S rDNA 염기서열을 유전자 은행상의 염기서열과 비교한 덴드로그램이다.1 is a dendogram comparing the 16S rDNA nucleotide sequence of the lactic acid bacteria of the present invention with the nucleotide sequence on the gene bank.
도 2는 본 발명의 유산균과 김치에서 분리한 다른 유산균들의 병원성 세균에 대한 항균력을 테스트한 결과를 비교한 그래프이다.Figure 2 is a graph comparing the results of testing the antimicrobial activity of pathogenic bacteria of lactic acid bacteria and other lactic acid bacteria isolated from kimchi of the present invention.
도 3은 본 발명의 락토바실러스 플란타륨 DSR 330(Lactobacillis plantarum DSR 330)유산균의 내산성을 나타낸 그래프이다.Figure 3 is a graph showing the acid resistance of Lactobacillus plantarum DSR 330 (Lactobacillis plantarum DSR 330) lactic acid bacteria of the present invention.
도 4는 본 발명의 락토바실러스 플란타륨 DSR 330(Lactobacillis plantarum DSR 330) 의 내염성을 나타낸 그래프이다.Figure 4 is a graph showing the flame resistance of the Lactobacillus plantarium DSR 330 (Lactobacillis plantarum DSR 330) of the present invention.
도 5는 본 발명의 락토바실러스 플란타륨 DSR 330(Lactobacillis plantarum DSR 330) 내담즙성을 나타낸 그래프이다. 5 is a graph showing the bile resistance of the Lactobacillus plantarum DSR 330 of the present invention (Lactobacillis plantarum DSR 330).
도 6은 본 발명의 락토바실러스 플란타륨 DSR 330(Lactobacillis plantarum DSR 330)을 현미경으로 관찰한 사진이다.Figure 6 is a photograph of the Lactobacillus plantarium DSR 330 (Lactobacillis plantarum DSR 330) of the present invention under a microscope.
<110> DAESANG FNF CORPORATION <120> Novel Lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use thereof <130> NP07-0116 <160> 1 <170> KopatentIn 1.71 <210> 1 <211> 858 <212> DNA <213> Lactobacillus plantarum <400> 1 gggggatcgg gtctatatga agtcgacgaa ctctggtatt gattggtgct tgctcatgat 60 ttacatttga gtgagtggcg aactggtgag taacacgtgg gaaacctgcc cagaagcggg 120 ggataacacc tggaaacaga tgctaatacc gcataacaac ttggaccgca tggtccgagc 180 ttgaaagatg gcttcggcta tcacttttga atggtcccgc ggcgtattag ctagatggtg 240 gggtaacggc tcaccatggc aatgatacgt agccgacctg agagggtaat cggccacatt 300 gggactgaga cacggcccaa actcctacgg gaggcagcag tagggaatct tccacaatgg 360 acgaaagtct gatggagcaa cgccgcgtga gtgaagaagg gtttcggctc gtaaaactct 420 gttgttaaag aagaacatat ctgagagtaa ctgttcaggt attgacggta tttaaccaga 480 aagccacggc taactacgtg ccagcagccg cggtaatacg taggtggcaa gcgttgtccg 540 gatttattgg gcgtaaagcg agcgcaggcg gttttttaag tctgatgtga aagccttcgg 600 ctcaaccgaa gaagtgcatc ggaaactggg aaacttgagt gcagaagaag acagtggaac 660 tccatgtgta gcggtgaaat gcgtagatat atggaagaac accagtgncg aaagcggctg 720 tctggtctgt aactgacgct gaagctcgna agtatgggta gccaacaaga ttagataccc 780 ctggtagtcc ataccgtaaa cgatgaatgc taagtgttgg gaaggtttcc gcccttcagt 840 gctgccacta aagccata 858 <110> DAESANG FNF CORPORATION <120> Novel Lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use <130> NP07-0116 <160> 1 <170> KopatentIn 1.71 <210> 1 <211> 858 <212> DNA <213> Lactobacillus plantarum <400> 1 gggggatcgg gtctatatga agtcgacgaa ctctggtatt gattggtgct tgctcatgat 60 ttacatttga gtgagtggcg aactggtgag taacacgtgg gaaacctgcc cagaagcggg 120 ggataacacc tggaaacaga tgctaatacc gcataacaac ttggaccgca tggtccgagc 180 ttgaaagatg gcttcggcta tcacttttga atggtcccgc ggcgtattag ctagatggtg 240 gggtaacggc tcaccatggc aatgatacgt agccgacctg agagggtaat cggccacatt 300 gggactgaga cacggcccaa actcctacgg gaggcagcag tagggaatct tccacaatgg 360 acgaaagtct gatggagcaa cgccgcgtga gtgaagaagg gtttcggctc gtaaaactct 420 gttgttaaag aagaacatat ctgagagtaa ctgttcaggt attgacggta tttaaccaga 480 aagccacggc taactacgtg ccagcagccg cggtaatacg taggtggcaa gcgttgtccg 540 gatttattgg gcgtaaagcg agcgcaggcg gttttttaag tctgatgtga aagccttcgg 600 ctcaaccgaa gaagtgcatc ggaaactggg aaacttgagt gcagaagaag acagtggaac 660 tccatgtgta gcggtgaaat gcgtagatat atggaagaac accagtgncg aaagcggctg 720 tctggtctgt aactgacgct gaagctcgna agtatgggta gccaacaaga ttagataccc 780 ctggtagtcc ataccgtaaa cgatgaatgc taagtgttgg gaaggtttcc gcccttcagt 840 gctgccacta aagccata 858
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20070105583A KR101485182B1 (en) | 2007-10-19 | 2007-10-19 | Novel Lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20070105583A KR101485182B1 (en) | 2007-10-19 | 2007-10-19 | Novel Lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090040025A true KR20090040025A (en) | 2009-04-23 |
KR101485182B1 KR101485182B1 (en) | 2015-01-22 |
Family
ID=40763627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20070105583A KR101485182B1 (en) | 2007-10-19 | 2007-10-19 | Novel Lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101485182B1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101345248B1 (en) * | 2011-09-23 | 2014-01-22 | 김매진 | Lactic acid bacteria for inhibiting the pathogenic bacteria and composition containing the same |
WO2014193014A1 (en) * | 2013-05-29 | 2014-12-04 | 바이오제닉스코리아 주식회사 | Nano-sized kimchi lactic acid bacteria |
KR101495309B1 (en) * | 2012-12-31 | 2015-02-26 | 대상에프앤에프 주식회사 | New lactic acid bacteria Lactobacillus plantarum DSR KF12 isolated from Gimchi and composition comprising the same |
KR20160027796A (en) * | 2014-09-02 | 2016-03-10 | 대한민국(농촌진흥청장) | Lactobacillus plantarum jsa22 strain and composition comprising the same |
US20160228480A1 (en) * | 2011-06-10 | 2016-08-11 | Amorepacific Corporation | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
KR102234836B1 (en) | 2020-01-31 | 2021-04-01 | 우진 비앤지 주식회사 | Composition for treating irritable bowel syndrome of companion animals comprising novel Lactobacillus Luteri LBR_C1 strain and novel Lactobacillus Ashdophilus LBA_C5 strain |
CN115093990A (en) * | 2022-06-01 | 2022-09-23 | 江南大学 | Lactic acid bacteria capable of inhibiting food spoilage bacteria in broad spectrum and application thereof |
KR20220133520A (en) * | 2021-03-25 | 2022-10-05 | 계명대학교 산학협력단 | A novel Lactobacillus plantarum KS2020 strain having GABA production activity, and method for preparing red ginseng fermented product or lacquer tree fermented product containing high concentration γ-PGA and GABA using the strain |
CN116716228A (en) * | 2023-07-24 | 2023-09-08 | 中国农业大学 | Lactobacillus plantarum EL6 with flavonoid content improving function and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100585391B1 (en) * | 2002-01-24 | 2006-06-01 | 주식회사 프로바이오닉 | Acid tolerant probiotic Lactobacillus plantarum Probio-38 that can suppresses the growth of pathogenic microorganisms and TGE coronavirus |
-
2007
- 2007-10-19 KR KR20070105583A patent/KR101485182B1/en active IP Right Grant
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9895402B2 (en) * | 2011-06-10 | 2018-02-20 | Amorepacific Corporation | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
US20160228480A1 (en) * | 2011-06-10 | 2016-08-11 | Amorepacific Corporation | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
US20160228478A1 (en) * | 2011-06-10 | 2016-08-11 | Amorepacific Corporation | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
US20160228479A1 (en) * | 2011-06-10 | 2016-08-11 | Amorepacific Corporation | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
US9889167B2 (en) * | 2011-06-10 | 2018-02-13 | Amorepacific Corporation | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
US9895401B2 (en) * | 2011-06-10 | 2018-02-20 | Amorepacific Corporation | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
KR101345248B1 (en) * | 2011-09-23 | 2014-01-22 | 김매진 | Lactic acid bacteria for inhibiting the pathogenic bacteria and composition containing the same |
KR101495309B1 (en) * | 2012-12-31 | 2015-02-26 | 대상에프앤에프 주식회사 | New lactic acid bacteria Lactobacillus plantarum DSR KF12 isolated from Gimchi and composition comprising the same |
WO2014193014A1 (en) * | 2013-05-29 | 2014-12-04 | 바이오제닉스코리아 주식회사 | Nano-sized kimchi lactic acid bacteria |
KR20140140387A (en) * | 2013-05-29 | 2014-12-09 | 바이오제닉스코리아 주식회사 | Nano-Sized Lactic Acid Bacteria from Kimchi |
US9763988B2 (en) | 2013-05-29 | 2017-09-19 | Biogenics Korea Co., Ltd. | Nano-sized kimchi lactic acid bacteria |
KR20160027796A (en) * | 2014-09-02 | 2016-03-10 | 대한민국(농촌진흥청장) | Lactobacillus plantarum jsa22 strain and composition comprising the same |
KR102234836B1 (en) | 2020-01-31 | 2021-04-01 | 우진 비앤지 주식회사 | Composition for treating irritable bowel syndrome of companion animals comprising novel Lactobacillus Luteri LBR_C1 strain and novel Lactobacillus Ashdophilus LBA_C5 strain |
KR20220133520A (en) * | 2021-03-25 | 2022-10-05 | 계명대학교 산학협력단 | A novel Lactobacillus plantarum KS2020 strain having GABA production activity, and method for preparing red ginseng fermented product or lacquer tree fermented product containing high concentration γ-PGA and GABA using the strain |
CN115093990A (en) * | 2022-06-01 | 2022-09-23 | 江南大学 | Lactic acid bacteria capable of inhibiting food spoilage bacteria in broad spectrum and application thereof |
CN115093990B (en) * | 2022-06-01 | 2023-08-25 | 江南大学 | Lactic acid bacteria capable of inhibiting food spoilage bacteria in broad spectrum and application thereof |
CN116716228A (en) * | 2023-07-24 | 2023-09-08 | 中国农业大学 | Lactobacillus plantarum EL6 with flavonoid content improving function and application thereof |
CN116716228B (en) * | 2023-07-24 | 2024-04-19 | 中国农业大学 | Lactobacillus plantarum EL6 with flavonoid content improving function and application thereof |
Also Published As
Publication number | Publication date |
---|---|
KR101485182B1 (en) | 2015-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101124056B1 (en) | Planted origine Lactobacillus plantarum DSR CK10, DSR M2 to keep freshness and use thereof | |
KR100911115B1 (en) | Novel lactic acid bacteria having acid resistance, bile-salt resistance and anti-bacterial effect and composition containing the same | |
KR101485182B1 (en) | Novel Lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use thereof | |
KR101381547B1 (en) | Novel Leuconostoc mesenteroides from kimchi with inhibiting activities on pathogenic microorganism and use thereof | |
KR20020023886A (en) | Novel Lactobacillus sp. Strain And Using The Same | |
KR20080109585A (en) | Novel plant origin lactic acid bacteria having acid resistance, bile salt-resistance, salt-resistance and anti-bacterial effect and composition containing the same | |
KR101960352B1 (en) | Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, bile resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amine and uses thereof | |
CN1819771A (en) | A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal | |
KR101834231B1 (en) | Vegetable Lactobacillus plantarum DSR KF15 having Activities on Antimicrobial And Antifungal for keeping freshness and Use Thereof | |
KR101993617B1 (en) | Lactobacillus pentosus SRCM101105 strain having antimicrobial activity and probiotics properties and uses thereof | |
KR101498272B1 (en) | Bacillus subtilis strain isolated from Kimchi, producing antimicrobial substances and having immune activity, and probiotics composition using it | |
KR102000475B1 (en) | Bacillus amyloliquefaciens NY12-2 strain having antibiotic activity against Bacillus cereus and inhibitory activity on biogenic amine and compositions thereof | |
KR100707102B1 (en) | Kimchi lactic acid bacteria inhibiting proliferation of Helicobacteria pylori and harmful microorganism method for preparing Kimchi using the same and use thereof | |
KR20160057855A (en) | Lactic acid bacterium separated from kimchii and having antifungal activity, and compositon including it | |
KR101005747B1 (en) | Lactic acid bacterium separated from kimchii and uses thereof | |
KR102130646B1 (en) | Novel lactobacillus salivarius and feed additives for aquacultural fish and crustacea comprising the same | |
KR101996080B1 (en) | Lactobacillus plantarum SRCM101594 strain having antimicrobial activity and probiotics properties and uses thereof | |
KR102424594B1 (en) | Lactobacillus fermentum OKBL-L.FE 1 strain having anti-inflammatory activity and antimicrobial activity against pathogenic microorganism and uses thereof | |
KR20070071911A (en) | Novel lactobacillus sakei and use thereof | |
KR100240687B1 (en) | Lactobacillus acidophilus ky 2104 and its uses | |
KR100803532B1 (en) | - DF20KCTC10942BP Lactobacillus salivarius sp. salivarius DF20 having been Acid-tolerant Bile-tolerant Antibacterial activity and possesed Alpha-galactosidase | |
KR20080102773A (en) | Novel plant-origin lactobacillus plantarum having activity for converting isoflavone into isoflavone aglycon and use thereof | |
EP2040723B1 (en) | Lactic acid bacterium with increased acid tolerance | |
KR100909452B1 (en) | New lactic acid bacteria and compositions containing them | |
KR100503570B1 (en) | Novel Pediococcus pentosaceus EROM101 having immune enhancement, anticancer and antibacterial activities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20200103 Year of fee payment: 6 |